


## Claims

- 1) A pharmaceutical preparation characterized by a content of at least one compound of general formula (I)



wherein R<sub>1</sub> and R<sub>2</sub> are each independently of each other a straight-chain or branched alkyl residue having 1 to 30 carbon atoms, a straight-chain or branched alkenyl residue having 2 to 30 carbon atoms, a monocyclic or polycyclic alkyl residue having 3 to 30 carbon atoms, a monocyclic or polycyclic alkenyl residue having 4 to 30 carbon atoms, or a monocyclic or polycyclic aromatic residue having 6 to 30 carbon atoms, these residues being optionally substituted by one or several substituents.

- 2) The pharmaceutical preparation according to claim 1, wherein in the compound of formula (I) R<sub>1</sub> and R<sub>2</sub> are a straight-chain C<sub>1-14</sub> alkyl residue or a C<sub>3-14</sub> cycloalkyl residue each.
- 3) The pharmaceutical preparation according to claim 1, in the compound of formula (I) wherein R<sub>1</sub> and R<sub>2</sub> are CH<sub>3</sub>CH<sub>2</sub> each.
- 4) The pharmaceutical preparation according to claim 1, wherein the compound of formula (I) is dimethylxanthogenate platinum (II) complex or diethylxanthogenate platinum (II) complex.
- 5) The pharmaceutical preparation according to claim 1, comprising additionally an immunosuppressive compound selected from the group consisting of cyclosporine, rapamycin, 15-deoxyspergualine, OKT3 and azathioprine.
- 6) The pharmaceutical preparation according to claim 1, comprising additionally cytokines, interferon or further cytostatic agents.
- 7) The pharmaceutical preparation according to claim 1, provided in a unit dosage form for administration to a mammal which requires treatment with an anticancer agent.

- 8) The pharmaceutical preparation according to claim 1 , further comprising a pharmaceutically compatible inert carrier or a diluent.
  - 9) Use of a pharmaceutical preparation according to claim 1 for treating a cancerous disease.
  - 10) Use according to claim 9, wherein the cancerous disease is the parvocellular bronchial carcinoma or colorectal carcinoma.
  - 11) A process for the production of a pharmaceutical preparation according to claim 1, characterized in that the compound according to formula (I) is mixed with a pharmaceutically compatible carrier or diluent.